New insider activity at Edwards Lifesciences ( (EW) ) has taken place on May 10, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Wayne Markowitz, the General Manager and Senior Vice President of Surgical at Edwards Lifesciences, recently executed a sale of 568 shares of the company’s stock, amounting to a total value of $42,594.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
Edwards Lifesciences demonstrates strong financial stability with a robust balance sheet and positive cash flow. Positive momentum in technical indicators supports the stock price, but a high P/E ratio suggests limited valuation upside. Recent earnings call highlights growth and strategic progress, though market challenges and tariff impacts pose risks. Corporate event initiatives further support long-term employee engagement.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
YTD Price Performance: 2.81%
Average Trading Volume: 4,719,123
Technical Sentiment Signal: Buy
Current Market Cap: $44.02B